TPOXX
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox
Conditions
Smallpox
Trial Timeline
Mar 29, 2022 → May 12, 2023
NCT ID
NCT04971109About TPOXX
TPOXX is a phase 3 stage product being developed by SIGA Technologies for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT04971109. Target conditions include Smallpox.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04971109 | Phase 3 | Completed |
| NCT04392739 | Approved | Completed |
Competing Products
20 competing products in Smallpox
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Smallpox vaccine, LISTER strain, from chick embryo cells | Sanofi | Phase 2 | 51 |
| MVA (smallpox vaccine) | Sanofi | Phase 1 | 32 |
| ACAM3000 MVA Vaccine | Sanofi | Phase 1 | 32 |
| MVA Smallpox vaccine + Placebo | Sanofi | Phase 2 | 51 |
| ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: Dryvax | Sanofi | Phase 2 | 51 |
| IMVAMUNE (MVA-BN) | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN | Bavarian Nordic | Phase 1 | 30 |
| IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE® | Bavarian Nordic | Phase 2 | 49 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| FD MVA-BN | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE® | Bavarian Nordic | Phase 3 | 74 |
| IMVAMUNE + IMVAMUNE | Bavarian Nordic | Phase 2 | 49 |
| MVA-BN® (IMVAMUNE) + Placebo | Bavarian Nordic | Phase 2 | 49 |
| Elstree-BN | Bavarian Nordic | Phase 1 | 30 |
| ACAM2000 | Emergent BioSolutions | Phase 3 | 69 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| ACAM2000® smallpox vaccine | Emergent BioSolutions | Pre-clinical | 15 |
| Brincidofovir | Emergent BioSolutions | Phase 1 | 25 |
| Vaccination with ACAM2000 | Emergent BioSolutions | Approved | 77 |
Other Products from SIGA Technologies
Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletApproved
77
TpoxxApproved
77
Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)Phase 3
69
tecovirimatPhase 3
69
ST-246 400 mg + ST-246 600 mg + PlaceboPhase 2
44